Campaigning For FDA’s Vote: New Drug Candidates For 2008 Approval
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Campaigning For FDA's Vote: New Drug Candidates For 2008 Approval
You may also be interested in...
The Year Ahead: Controversial NDAs Could Entangle FDA In ‘08; Where Are The Oncologics?
Looking ahead at FDA’s review calendar for 2008, the agency will be wrestling with several enigmatic decisions as it considers applications for fibromyalgia and chronic fatigue syndrome, controversial diseases with nebulous definitions and diagnoses.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product